Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 7/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5917036 | 0.89 | POLB (0.59) | POLBCCR1CNR2CNR1MEN1 | |
| SCHEMBL5917035 | 0.89 | POLB (0.59) | POLBCCR1CNR2CNR1MEN1 | |
| SCHEMBL9830901 | 0.89 | POLB (0.59) | POLBCCR1CNR2CNR1MEN1 | |
| SCHEMBL16114864 | 0.89 | POLB (0.59) | POLBCCR1CNR2CNR1MEN1 | |
| SCHEMBL21186412 | 0.88 | POLB (0.57) | POLBCCR1CNR2CNR1MEN1 | |
| SCHEMBL21186380 | 0.87 | POLB (0.56) | POLBCCR1CNR2CNR1MEN1 | |
| SCHEMBL16140159 | 0.85 | POLB (0.55) | POLBCCR1CNR2CNR1MEN1 | |
| SCHEMBL17600390 | 0.82 | ELANE (0.53) | POLBCCR1CNR2CNR1MEN1 | |
| SCHEMBL19899091 | 0.82 | ELANE (0.53) | POLBCCR1CNR2CNR1MEN1 | |
| SCHEMBL19591984 | 0.79 | POLB (0.76) | POLBCNR2MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | THE GENERAL HOSPITAL CORPORATION | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | GZMB, CTSB, PRF1 | POLB 681/4885CCR1 457/4885CNR2 4792/4885 |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | GZMB, CTSB, PRF1 | POLB 681/4885CCR1 457/4885CNR2 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.